Results 71 to 80 of about 1,183 (178)

Blood‐Based Circulating Tumor DNA Assays for Early Colorectal Cancer Detection: A Systematic Review of Performance in Asymptomatic Screening Populations

International Journal of Cancer, Volume 159, Issue 4, Page 1028-1041, 15 August 2026.
Early detection of colorectal cancer via population‐based screening programs can reduce incidence and mortality, but current screening approaches are limited. This systematic review evaluated the screening potential of blood‐based circulating tumor DNA assays in asymptomatic screening populations.
Caroline Ledertoug Kahn, Maria Wissing Rasmussen, Jakob Kleif, Inge Søkilde Pedersen, Christina Therkildsen   +4 more
wiley   +1 more source

Beyond Mutation Detection: Cell-Free DNA for Functional Inference and Adaptive Oncology

DNA
Liquid biopsy has evolved beyond its original role as a minimally invasive approach for mutation detection and is now being developed as a broader analytical framework for cancer detection, stratification, and longitudinal monitoring.
Tetiana Zaichuk
doaj   +1 more source

Circulating Mitochondrial DNA Measures Across Malignancies: Diagnostic Accuracy and Prognostic Associations

Cancer Medicine, Volume 15, Issue 8, August 2026.
ABSTRACT Background Circulating mitochondrial DNA is being investigated as a liquid‐biopsy biomarker because of its high copy number and release during cellular stress. However, diagnostic estimates vary across tumor types and assays, and prognostic studies have measured both cell‐free mtDNA and cellular blood‐derived mtDNA, which are not analytically ...
Ziying Zhang, Ying Jiang, Yu Gong, Hui Xie, Yaqian Han, Peng Chen   +5 more
wiley   +1 more source

Early detection of malignant and premalignant peripheral nerve tumors using cell-free DNA fragmentomics [PDF]

PURPOSE: Early detection of neurofibromatosis type 1 (NF1)-associated peripheral nerve sheath tumors (PNST) informs clinical decision-making, enabling early definitive treatment and potentially averting deadly outcomes.
Burgic, Sanita, Chrisinger, John S A, et al.,, Hirbe, Angela C, Armstrong, Amy E, Sundby, R Taylor, Srihari, Divya, Weekley, Kara, Chamberlain, Stacey, Jones, Paul A   +9 more
core   +1 more source

Applications of Artificial Intelligence in Cancer Diagnosis and Treatment

Cancer Medicine, Volume 15, Issue 8, August 2026.
This review explores how AI and multimodal data fusion transform oncology through enhanced screening, precision diagnosis, and personalized therapy. By dissecting core challenges—including data bias and explainability—it provides a strategic framework for the digital transformation and ethical implementation of AI in clinical cancer care.
Yifeng Xie, Zixuan Wang, Zhiwen Zeng, Tongyao Xin, Shaofei Yuan, Feiwei Qin, Zhonglin Chen   +6 more
wiley   +1 more source

Liquid biopsy biomarkers for early detection of gastrointestinal cancers: Current landscape and emerging technologies

Clinical and Translational Medicine
Early detection of gastrointestinal (GI) cancers remains a critical unmet clinical need, as most patients are diagnosed at advanced stages when prognosis is poor.
Muhammad Anees, Christopher Sherry, Hyun Y. Park, Erin E. Grayhack, Arul Goel, Alisha F. Khan, Ashten Omstead, David L. Bartlett, Ajay Goel, Neda Dadgar, Patrick L. Wagner, Ali H. Zaidi   +11 more
doaj   +1 more source

Cell-Free Mitochondrial DNA in Cell Culture Supernatant: Fragment Size Analysis and FBS Contamination Assessment

DNA
Background/Objectives: Circulating cell-free DNA (cfDNA) consists of genomic DNA (cf-nDNA) and mitochondrial DNA (cf-mtDNA) fragments released from cells primarily through apoptosis and necrosis.
Patrizia Cesare, Sabrina Colafarina, Antonella Bonfigli, Anna Rita Volpe, Massimo Aloisi, Osvaldo Zarivi, Anna Maria Giuseppina Poma   +6 more
doaj   +1 more source

Multidimensional fragmentomic profiling of cell-free DNA released from patient-derived organoids

Human Genomics, 2023
Background Fragmentomics, the investigation of fragmentation patterns of cell-free DNA (cfDNA), has emerged as a promising strategy for the early detection of multiple cancers in the field of liquid biopsy.
Jaeryuk Kim, Seung-Pyo Hong, Seyoon Lee, Woochan Lee, Dakyung Lee, Rokhyun Kim, Young Jun Park, Sungji Moon, Kyunghyuk Park, Bukyoung Cha, Jong-Il Kim   +10 more
doaj   +1 more source

An Epstein‐Barr Virus Nuclear Antigen 1 (EBNA1) Serology Test Strip for Nasopharyngeal Carcinoma Risk Screening

Journal of Medical Virology, Volume 98, Issue 8, August 2026.
ABSTRACT Antibodies to Epstein‐Barr virus (EBV) proteins can predict nasopharyngeal carcinoma (NPC) risk. We previously defined a prototype EBNA1 protein panel and multiplex immunoblot assay that distinguishes NPC risk several years pre‐diagnosis.
Benjamin E. Warner, Japan Patel, Rebecca Satterwhite, Renwei Wang, Jennifer Adams‐Haduch, Woon‐Puay Koh, Jian‐Min Yuan, Kathy H. Y. Shair   +7 more
wiley   +1 more source

Letter to the Editor: An ultra-sensitive assay using cell-free DNA fragmentomics for multi-cancer early detection

Molecular Cancer, 2022
Early detection can benefit cancer patients with more effective treatments and better prognosis, but existing early screening tests are limited, especially for multi-cancer detection.
Hua Bao, Zheng Wang, Xiaoji Ma, Wei Guo, Xiangyu Zhang, Wanxiangfu Tang, Xin Chen, Xinyu Wang, Yikuan Chen, Shaobo Mo, Naixin Liang, Qianli Ma, Shuyu Wu, Xiuxiu Xu, Shuang Chang, Yulin Wei, Xian Zhang, Hairong Bao, Rui Liu, Shanshan Yang, Ya Jiang, Xue Wu, Yaqi Li, Long Zhang, Fengwei Tan, Qi Xue, Fangqi Liu, Sanjun Cai, Shugeng Gao, Junjie Peng, Jian Zhou, Yang Shao   +31 more
doaj   +1 more source